The global anti-infectives market size reached USD 138.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 180.0 Billion by 2033, exhibiting a growth rate (CAGR) of 2.93% during 2025-2033.
Anti-infectives are medicines that act against infections, either by inhibiting the spread or killing the infectious agent outright. These medicines include antibiotics, antivirals, antifungals, antimalarials, anthelmintics, and antiprotozoals. They are generally administered through oral, parenteral, and topical routes. They are widely used to treat minor infectious diseases, including pneumonia and tuberculosis. Apart from this, anti-infectives are also utilized during routine procedures and surgeries, such as cesarian section and joint replacement, which are associated with a high risk of severe infection.
Anti-infectives Market Trends:
The global anti-infectives market is primarily driven by rising incidences of infectious diseases across the globe. Anti-Infinitives are used to treat infections, including viruses, bacteria, parasites, and fungi. Additionally, the development of novel drugs that are formulated using different strategies, such as natural products, quorum sensing inhibitors, biofilm disruptors, gallium-based drugs, cyclodextrin inhibitors, and light-based antimicrobials, are providing an impetus to the market growth. In line with this, the latest innovations in drug discovery procedures, such as stem cells and organ-on-chip (OOC) technologies, to enhance drug trial processes are creating a positive outlook for the market. Furthermore, the increasing product adoption due to the advent of the COVID-19 disease and induced infections, such as aspergillosis, invasive candidiasis, and mucormycosis, is strengthening the growth of the market. Besides this, the increasing number of new anti-infective drugs being approved by the regulatory authorities is acting as another growth-inducing factor. Moreover, the implementation of favorable government policies, rising investments in developing new and innovative drugs, increasing awareness among individuals about infectious diseases, and rapidly improving healthcare infrastructure are anticipated to impel the growth of the market in the coming years.
Key Market Segmentation:
Breakup by Type:
Antibacterial
Antifungal
Antiviral
Breakup by Route of Administration:
Topical
Oral
Intravenous (IV)
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Speciality Pharmacies
Online Stores
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Cipla Health Ltd. (Cipla Limited), F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson, Lupin Limited, Sandoz AG (Novartis AG) and Sun Pharmaceutical Industries Limited.
Key Questions Answered in This Report
1.What was the size of the global anti-infectives market in 2024?
2.What is the expected growth rate of the global anti-infectives market during 2025-2033?
3.What are the key factors driving the global anti-infectives market?
4.What has been the impact of COVID-19 on the global anti-infectives market?
5.What is the breakup of the global anti-infectives market based on the type?
6.What is the breakup of the global anti-infectives market based on the route of administration?
7.What is the breakup of the global anti-infectives market based on distribution channel?
8.What are the key regions in the global anti-infectives market?
9.Who are the key players/companies in the global anti-infectives market?